Abiomed Impella 2.5 and 5.0:
This article was originally published in Clinica
Abiomed has received Canadian approval for its Impella 2.5 and Impella 5.0 ventricular cardiac assist devices for maintaining circulatory support. The devices are inserted minimally invasively into the left ventricle, where they help pump blood in heart failure patients. The Danvers, Massachusetts company has already CE marked the Impella 2.5 for sale in Europe, and Abiomed has now completed enrolment in a pilot study of the technology in the US. The Impella 5.0, which can also be inserted surgically, is CE-marked too, and is in pilot studies in the US.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.